Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza Signs PACTs For Biomanufacturing

by Michael McCoy
November 16, 2009 | A version of this story appeared in Volume 87, Issue 46

The Swiss contract manufacturer Lonza will manufacture Arzerra, a monoclonal antibody developed by GlaxoSmithKline and Genmab for the treatment of chronic lymphocytic leukemia. Arzerra was recently approved by FDA. Separately, Lonza’s Hopkinton, Mass., facility will manufacture ProChon Biotech’s fibroblast growth factor, a component of the Woburn, Mass., firm’s BioCart cartilage regeneration system. BioCart is now in clinical trials across the U.S., ProChon says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.